INS and Insulin resistance: Since the commonly used insulin sensitizer thiazolidinediones, selective agonists for nuclear peroxisomal proliferator-activated receptor-γ, have been reported to be associated with increased risk of massive hepatic necrosis, heart failure, and bladder cancer in patients treated with these drugs [6]–[8], it is of great value to identify new therapeutic targets for development of novel therapy against insulin resistance.